Navigation Links
Shire Changes its NASDAQ Ticker Symbol to SHPG
Date:7/9/2012

DUBLIN, Ireland, July 9, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the NASDAQ ticker symbol for Shire's American Depositary Shares ("ADSs") will change from "SHPGY" to "SHPG" on and from the opening of NASDAQ trading on July 11, 2012.

Each ADS continues to represent 3 ordinary shares of Shire plc.

The London Stock Exchange ticker symbol for Shire plc's ordinary shares remains "SHP".

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact:

         Investor Relations     Eric Rojas                         erojas@shire.com          +1-781-482-0999     Sarah Elton-Farr                  seltonfarr@shire.com     +44(0)1256-894157


'/>"/>
SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
2. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
5. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
6. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
7. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
8. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
9. NYSE Companies and NASDAQ Companies June 7th Investor Presentations Now Available at RetailInvestorConferences.com
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Sequenom Named to NASDAQ Global Select Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , ... January 23, 2017 , ... ... at the Caribbean Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica from ... and host a hands-on workshop for surgeons to experience the simplicity of the ...
(Date:1/21/2017)... ... January 20, 2017 , ... Nipro Corporation (Osaka, Japan) and ... under which Nipro will receive exclusive marketing and sales rights for all non-OEM Transonic ... for hemodialysis patients in Japan, the new Nipro - Transonic JV is a natural ...
(Date:1/21/2017)... 20, 2017 Bioptix, Inc. (Nasdaq: ... that on January 14, 2017 the Board of Directors ... Company will terminate certain employees associated with the September ... Company commenced terminations on January 16, 2017 and terminations ... Company may pay severance benefits in certain circumstances of ...
(Date:1/20/2017)... PA (PRWEB) , ... January 20, 2017 , ... The ... transforming healthcare treatment options for patients. Vironika, a spin out from The Wistar Institute, ... both taking lab space at 3624 Market Street. , Vironika is developing a ...
Breaking Biology Technology:
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
(Date:12/7/2016)... , Dec. 7, 2016   Avanade ... successful Formula One teams in history, exploit biometric data ... stop performance and maintain the competitive edge against their ... 2016. Avanade has worked with Williams ... range of biometric data (heart rate, breathing rate, temperature ...
Breaking Biology News(10 mins):